Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedSep 02, 2025
DataAggregated Company Financials
Companies21
  • 7D-0.1%
  • 3M-16.8%
  • 1Y-55.6%
  • YTD-37.6%

Last week, the Healthcare industry hasn't moved much but Genmab is up 4.2% in that time. Unfortunately though, the industry is down 56% over the past 12 months. Looking forward, earnings are forecast to grow by 8.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 02 Sep 2025DKK 2.1tDKK 447.4bDKK 141.7b24.4x14.9x4.7x
Thu, 31 Jul 2025DKK 1.9tDKK 423.8bDKK 124.7b29.5x15.2x4.5x
Sat, 28 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Mon, 26 May 2025DKK 2.4tDKK 424.3bDKK 125.1b23.4x19.4x5.7x
Wed, 23 Apr 2025DKK 2.2tDKK 409.2bDKK 121.3b20.8x17.9x5.3x
Fri, 21 Mar 2025DKK 2.9tDKK 409.5bDKK 121.3b25.2x24x7.1x
Sun, 16 Feb 2025DKK 3.0tDKK 409.9bDKK 121.5b26.3x24.9x7.4x
Tue, 14 Jan 2025DKK 3.3tDKK 387.5bDKK 111.4b29.4x29.4x8.4x
Thu, 12 Dec 2024DKK 4.1tDKK 387.4bDKK 111.3b31.2x36.5x10.5x
Sat, 09 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Mon, 07 Oct 2024DKK 4.0tDKK 372.0bDKK 107.1b35.8x37.5x10.8x
Wed, 04 Sep 2024DKK 4.7tDKK 372.0bDKK 107.2b35x44.2x12.7x
Fri, 02 Aug 2024DKK 4.7tDKK 355.4bDKK 106.3b36.7x44x13.2x
Sun, 30 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.1x47.4x14.2x
Tue, 28 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.4x43.8x13.1x
Thu, 25 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b33.8x45.1x13.2x
Sat, 23 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Mon, 19 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.9x44.3x12.9x
Wed, 17 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.4x42.1x11.8x
Fri, 15 Dec 2023DKK 3.5tDKK 320.4bDKK 90.0b33.2x38.7x10.9x
Sun, 12 Nov 2023DKK 3.6tDKK 319.8bDKK 89.9b31.7x39.6x11.1x
Tue, 10 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b32.5x41x11x
Thu, 07 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.2x42.6x11.5x
Sat, 05 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Mon, 03 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b40.3x39.9x10.5x
Wed, 31 May 2023DKK 3.1tDKK 287.1bDKK 75.5b41x40.6x10.7x
Fri, 28 Apr 2023DKK 3.1tDKK 272.6bDKK 69.0b44.3x44.8x11.3x
Sun, 26 Mar 2023DKK 2.9tDKK 291.2bDKK 69.0b36.7x42.1x10x
Tue, 21 Feb 2023DKK 2.8tDKK 289.4bDKK 68.9b40x40.3x9.6x
Thu, 19 Jan 2023DKK 2.7tDKK 276.0bDKK 66.3b39.1x41.3x9.9x
Sat, 17 Dec 2022DKK 2.7tDKK 276.1bDKK 66.3b37.7x40x9.6x
Mon, 14 Nov 2022DKK 2.4tDKK 276.0bDKK 66.6b35x36x8.7x
Wed, 12 Oct 2022DKK 2.3tDKK 261.4bDKK 62.4b33.7x37.1x8.9x
Fri, 09 Sep 2022DKK 2.3tDKK 261.2bDKK 62.4b35x37.6x9x
Price to Earnings Ratio

37.6x


Total Market Cap: DKK 2.3tTotal Earnings: DKK 62.4bTotal Revenue: DKK 261.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 36.7x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 14.9x which is lower than its 3-year average PE of 36.7x.
  • The 3-year average PS ratio of 10.1x is higher than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 20% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.62%
Healthcare-0.14%
Healthcare Services8.11%
Biotech4.03%
Life Sciences1.57%
Healthtech0.74%
Medical Equipment-0.38%
Pharma-0.48%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 23.4x.
    • Analysts are expecting annual earnings growth of 60.4%, which is higher than its past year's earnings decline of 47.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 65% over the next 5 years.
  • This is better than its past earnings decline of 83% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 358.452.1%
+DKK 33.3b		-61.3%PE14.3x
GMAB GenmabDKK 1.65k4.7%
+DKK 4.6b		-11.7%PE11.6x
ZEAL Zealand PharmaDKK 444.306.3%
+DKK 1.9b		-49.6%PE4.7x
HLUN B H. LundbeckDKK 40.102.6%
+DKK 1.0b		-16.5%PE11.4x
GUBRA GubraDKK 391.204.0%
+DKK 245.2m		-26.7%PE3.7x

Latest News

DEMANT
DKK 238.40
Demant
7D
-1.3%
1Y
-16.6%

Demant (CPH:DEMANT) Is Doing The Right Things To Multiply Its Share Price

Sep 02
Demant (CPH:DEMANT) Is Doing The Right Things To Multiply Its Share Price
NOVO B
DKK 358.45
Novo Nordisk
7D
2.1%
1Y
-61.3%
COLO B
DKK 609.60
Coloplast
7D
-0.1%
1Y
-34.8%

Chronic Care Focus And Emerging Markets Will Redefine Healthcare

Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.
ZEAL
DKK 444.30
Zealand Pharma
7D
6.3%
1Y
-49.6%

Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Aug 29
Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
STENO
DKK 1.28
Stenocare
7D
-20.1%
1Y
-50.6%
BAVA
DKK 235.70
Bavarian Nordic
7D
-1.4%
1Y
-9.0%

VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues

Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.
AMBU B
DKK 95.60
Ambu
7D
-2.6%
1Y
-26.4%

Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 27
Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
HLUN B
DKK 40.10
H. Lundbeck
7D
2.6%
1Y
-16.5%
GUBRA
DKK 391.20
Gubra
7D
4.0%
1Y
-26.7%
ALK B
DKK 202.20
ALK-Abelló
7D
0.2%
1Y
14.9%

Allergy+ Strategy Will Reach Millions With New Therapies

The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
VIRO
DKK 9.58
ViroGates
7D
-10.0%
1Y
55.8%
BIOPOR
DKK 1.39
BioPorto
7D
8.1%
1Y
-29.8%
GMAB
DKK 1,652.00
Genmab
7D
4.7%
1Y
-11.7%
NNIT
DKK 62.60
NNIT
7D
1.1%
1Y
-40.7%

Integration And New Systems In 2024 Will Streamline Operations And Lower Costs

NNIT’s consensus price target has been revised down to DKK80.00, primarily reflecting lowered revenue growth and a slight decline in net profit margin. Valuation Changes Summary of Valuation Changes for NNIT The Consensus Analyst Price Target has fallen from DKK85.00 to DKK80.00.
EMBLA
DKK 31.90
Embla Medical hf
7D
-1.5%
1Y
3.9%

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Aug 08
Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
STRAP
DKK 962.00
Strategic Partners
7D
-7.5%
1Y
13.2%